Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform, explains how her organization is helping employers better understand accountable care organizations (ACOs) and judge how the ACO model might work with their population.
Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform, explains how her organization is helping employers better understand accountable care organizations (ACOs) and judge how the ACO model might work with their population.
Transcript
Catalyst for Payment Reform recently tried to measure the prevalence of ACOs. What did you find and what challenges did you run into?
For a project that we have called, Scorecard 2.0, where we’re trying to measure how much payment reform there is, what type, and what changes that’s lead to in the healthcare system. We wanted to measure the prevalence of ACOs, and we found that it was virtually impossible to do. We consulted all the leading experts in the country who have been trying to do this, because there’s not one definition of an ACO. So, even when we tried to come up with ideas to test providers who come together with responsibility for a given population of patients supported by an alternative payment model, there were challenges to that definition. Unfortunately, for now, we haven’t found a very good way to track ACOS.
Catalyst for Payment Reform also created a toolkit for employers on ACO arrangements. What does the toolkit include and how can employers use it?
Employers were feeling frustrated by the lack of transparency that they had into their health plan’s ACO arrangements. Health plans are touting how many ACO contracts they have and sharing some results, but they felt cherry picked and not comprehensive or as meaningful as employers wanted those results to be. They want to make decisions whether or not they should back this approach and seek it proactively for their population members.
So, we pulled employers together who were feeling this frustration and worked over a year to come up with the kinds of information they would want to know from their health plans, and then, we turned that into a standard template report that employers can ask their health plans to use in sharing results of their ACO arrangements. The hope is that employers will be able to better judge how effective this movement is, work with the health plan on ACOs that are not so effective to try to help it improve, or maybe move on to something else, and ultimately have a better understanding of how well the ACO model might work for their population over time.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More